» Articles » PMID: 37664452

Predicting Breast Cancer-specific Survival in Metaplastic Breast Cancer Patients Using Machine Learning Algorithms

Overview
Journal J Pathol Inform
Date 2023 Sep 4
PMID 37664452
Authors
Affiliations
Soon will be listed here.
Abstract

Metaplastic breast cancer (MpBC) is a rare and aggressive subtype of breast cancer, with data emerging on prognostic factors and survival prediction. This study aimed to develop machine learning models to predict breast cancer-specific survival (BCSS) in MpBC patients, utilizing a dataset of 160 patients with clinical, pathological, and biological variables. An in-depth variable selection process was carried out using gain ratio and correlation-based methods, resulting in 10 variables for model estimation. Five models (decision tree with bagging; logistic regression; multilayer perceptron; naïve Bayes; and, random forest algorithms) were evaluated using 10-fold cross-validation. Despite the constraints posed by the absence of therapeutic information, the random forest model exhibited the highest performance in predicting BCSS, with an ROC area of 0.808. This study emphasizes the potential of machine learning algorithms in predicting prognosis for complex and heterogeneous cancer subtypes using clinical datasets, and their potential to contribute to patient management. Further research that incorporates additional variables, such as treatment response, and more advanced machine learning techniques will likely enhance the predictive power of MpBC prognostic models.

Citing Articles

Novel models based on machine learning to predict the prognosis of metaplastic breast cancer.

Zhang Y, An W, Wang C, Liu X, Zhang Q, Zhang Y Breast. 2024; 79:103858.

PMID: 39675092 PMC: 11699302. DOI: 10.1016/j.breast.2024.103858.


Conditional generative adversarial network driven radiomic prediction of mutation status based on magnetic resonance imaging of breast cancer.

Huang Z, Chen L, Sun Y, Liu Q, Hu P J Transl Med. 2024; 22(1):226.

PMID: 38429796 PMC: 10908206. DOI: 10.1186/s12967-024-05018-9.

References
1.
Al-Hilli Z, Choong G, Keeney M, Visscher D, Ingle J, Goetz M . Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy. Breast Cancer Res Treat. 2019; 176(3):709-716. PMC: 7469521. DOI: 10.1007/s10549-019-05264-2. View

2.
Lopez G, Noale M, Corti C, Gaudioso G, Sajjadi E, Venetis K . PTEN Expression as a Complementary Biomarker for Mismatch Repair Testing in Breast Cancer. Int J Mol Sci. 2020; 21(4). PMC: 7073136. DOI: 10.3390/ijms21041461. View

3.
Tonellotto F, Bergmann A, Abrahao K, de Aguiar S, Bello M, Thuler L . Impact of Number of Positive Lymph Nodes and Lymph Node Ratio on Survival of Women with Node-Positive Breast Cancer. Eur J Breast Health. 2019; 15(2):76-84. PMC: 6456272. DOI: 10.5152/ejbh.2019.4414. View

4.
Zhang S, Jing Y, Zhang M, Zhang Z, Ma P, Peng H . Stroma-associated master regulators of molecular subtypes predict patient prognosis in ovarian cancer. Sci Rep. 2015; 5:16066. PMC: 4632004. DOI: 10.1038/srep16066. View

5.
He X, Ji J, Dong R, Liu H, Dai X, Wang C . Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis. Breast Cancer Res Treat. 2018; 173(2):329-341. DOI: 10.1007/s10549-018-5005-6. View